COM:CRISPRTX
CRISPR Therapeutics AG
- Stock
Last Close
46.29
22/11 21:00
Market Cap
4.72B
Beta: -
Volume Today
1.50M
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '14 | Dec '15 | Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
average inventory | -5.60M - | ||||||||||
average payables | 897.50K - | 3.08M 242.79% | 3.10M 0.89% | 3.35M 8.05% | 5.51M 64.18% | 7.52M 36.55% | 11.96M 59.00% | 21.12M 76.68% | 32.79M 55.23% | ||
average receivables | 169.50K - | 1.75M 931.27% | 2.89M 65.42% | 1.36M 53.07% | 93.50K 93.11% | 121.50K 29.95% | 224.50K 84.77% | 152.50K 32.07% | 105.60M 69,145.90% | ||
book value per share | -0.24 - | -0.99 308.84% | 19.00 2,012.73% | 4.69 75.32% | 8.18 74.38% | 17.27 111.22% | 25.23 46.11% | 31.59 25.20% | 24.12 23.64% | 23.77 1.48% | |
capex per share | -0.04 - | -0.25 524.68% | -0.20 20.72% | -0.06 70.36% | -0.12 112.55% | -0.28 126.52% | -1.08 286.47% | -0.48 55.54% | -0.15 68.41% | ||
capex to depreciation | -9.09 - | -3.26 64.12% | -2.58 20.75% | -0.79 69.50% | -1.41 79.52% | -2.00 41.31% | -4.55 127.68% | -1.54 66.20% | -0.60 60.78% | ||
capex to operating cash flow | -0.02 - | 0.05 380.81% | 0.11 104.43% | 0.03 74.15% | -0.12 509.29% | 0.08 165.31% | -0.15 296.83% | 0.08 149.48% | 0.05 38.72% | ||
capex to revenue | -4.67 - | -0.58 87.50% | -0.19 67.37% | -0.89 365.71% | -0.02 97.40% | -33.81 146,378.09% | -0.09 99.74% | -85.29 95,218.46% | -0.03 99.96% | ||
cash per share | 0.03 - | 5.32 16,403.81% | 25.74 383.55% | 5.99 76.75% | 9.52 59.06% | 17.35 82.25% | 25.63 47.72% | 31.33 22.22% | 23.35 25.46% | 21.38 8.44% | |
days of inventory on hand | |||||||||||
days payables outstanding | 90.80 - | 106.90 17.72% | |||||||||
days sales outstanding | 500.95 - | 223.14 55.46% | 23.38 89.52% | 10.28 56.02% | 0.12 98.79% | 96.80 77,473.08% | 0.12 99.87% | 197.30 - | |||
debt to assets | 0.24 - | -0.17 172.66% | -0.16 6.79% | -0.07 55.65% | 0.05 168.18% | 0.03 31.77% | 0.08 143.34% | 0.11 33.04% | 0.11 1.62% | ||
debt to equity | -1.32 - | -0.26 80.35% | -0.24 9.11% | -0.09 61.72% | 0.06 162.09% | 0.04 34.00% | 0.09 154.08% | 0.13 38.74% | 0.13 2.59% | ||
dividend yield | |||||||||||
earnings yield | -0.02 - | -0.06 279.82% | -0.09 49.33% | -0.07 22.21% | -0.12 65.65% | 0.02 116.76% | -0.03 271.19% | 0.07 289.93% | -0.21 413.52% | -0.03 84.94% | |
enterprise value | 411.86M - | 295.18M 28.33% | -67.18M 122.76% | 700.79M 1,143.10% | 913.69M 30.38% | 2.42B 165.03% | 8.99B 271.27% | 5.06B 43.75% | 3.19B 36.87% | 4.81B 50.61% | |
enterprise value over ebitda | -60.35 - | -11.54 80.88% | 2.66 123.09% | -11.37 526.98% | -5.75 49.45% | 51.81 1,001.24% | -26.04 150.26% | 13.54 151.99% | -4.74 135.03% | -23.72 400.18% | |
ev to operating cash flow | -85.93 - | 4.97 105.78% | 1.21 75.55% | -10.00 923.06% | -9.49 5.04% | 42.73 550.02% | -37.72 188.28% | 9.38 124.88% | -6.44 168.63% | -18.47 186.76% | |
ev to sales | 1.20K - | -13.01 101.09% | 17.09 231.39% | 292.48 1,611.02% | 8.36 97.14% | 16.56K 197,902.60% | 5.54 99.97% | 7.32K 132,100.14% | 13.00 99.82% | ||
free cash flow per share | -0.16 - | 1.99 1,315.81% | -4.76 339.23% | -1.94 59.13% | -2.06 6.13% | 0.92 144.52% | -3.89 523.53% | 6.02 254.67% | -6.85 213.85% | -3.44 49.85% | |
free cash flow yield | -0.01 - | 0.14 1,315.81% | -0.23 266.38% | -0.08 64.73% | -0.07 12.78% | 0.02 120.89% | -0.03 268.47% | 0.08 412.50% | -0.17 312.24% | -0.05 67.43% | |
graham net net | -0.26 - | -1.10 327.90% | 16.79 1,621.21% | 3.95 76.47% | 7.50 89.97% | 15.01 100.07% | 23.15 54.21% | 26.69 15.29% | 18.62 30.23% | 18.90 1.47% | |
graham number | 1.13 - | 4.44 294.06% | 28.44 540.86% | 13.42 52.83% | 25.16 87.48% | 21.86 13.12% | 54.80 150.76% | 59.45 8.48% | 67.37 13.32% | 32.20 52.21% | |
income quality | 0.70 - | -2.30 426.44% | 2.38 203.60% | 1.03 56.98% | 0.58 43.11% | 0.85 45.32% | 0.68 19.40% | 1.43 108.87% | 0.76 46.57% | 1.70 122.31% | |
intangibles to total assets | 0.33 - | 0.00 99.15% | 0.00 59.38% | 0.00 9.61% | 0.00 53.38% | 0.00 62.72% | 0.00 55.30% | 0.00 53.87% | 0.00 30.32% | 0.00 77.33% | |
interest coverage | -238.23 - | -8.46 96.45% | 14.37 - | ||||||||
interest debt per share | 1.31 - | -4.26 424.71% | -1.10 74.11% | -0.74 33.25% | 0.97 231.16% | 0.93 3.57% | 2.96 218.10% | 2.54 14.40% | 3.01 18.77% | ||
inventory turnover | |||||||||||
invested capital | -1.32 - | -0.26 80.35% | -0.24 9.11% | -0.09 61.72% | 0.06 162.09% | 0.04 34.00% | 0.09 154.08% | 0.13 38.74% | 0.13 2.59% | ||
market cap | 412.81M - | 412.81M 0% | 248.34M 39.84% | 940.55M 278.74% | 1.37B 45.70% | 3.31B 141.75% | 10.10B 204.81% | 5.76B 43.00% | 3.16B 45.09% | 4.96B 56.92% | |
net current asset value | -7.53M - | -31.71M 320.91% | 208.07M 756.23% | 164.87M 20.76% | 369.57M 124.16% | 860.22M 132.76% | 1.55B 80.52% | 2.07B 32.98% | 1.49B 28.07% | 1.56B 5.11% | |
net debt to ebitda | 0.14 - | 4.60 3,220.23% | 12.51 172.08% | 3.89 68.90% | 2.87 26.16% | -19.07 763.68% | 3.21 116.82% | -1.87 158.27% | -0.05 97.45% | 0.74 1,658.84% | |
net income per share | -0.23 - | -0.88 279.82% | -1.89 114.72% | -1.71 9.85% | -3.44 101.56% | 1.23 135.74% | -5.29 530.36% | 4.97 194.00% | -8.36 268.18% | -1.94 76.81% | |
operating cash flow per share | -0.16 - | 2.03 1,339.89% | -4.51 322.46% | -1.75 61.22% | -2.01 14.66% | 1.04 151.93% | -3.61 446.87% | 7.10 296.34% | -6.38 189.85% | -3.29 48.46% | |
payables turnover | 4.02 - | 3.41 15.06% | |||||||||
receivables turnover | 0.73 - | 1.64 124.50% | 15.61 854.43% | 35.50 127.39% | 2.93K 8,139.86% | 3.77 99.87% | 2.99K 79,291.16% | 1.85 - | |||
research and ddevelopement to revenue | 50.90 - | 8.18 83.93% | 1.70 79.18% | 36.42 2,039.07% | 0.62 98.30% | 491.61 79,273.72% | 0.48 99.90% | 1.06K 220,309.17% | 1.05 99.90% | ||
return on tangible assets | -6.68 - | -0.16 97.57% | -0.07 58.55% | -0.25 274.59% | -0.34 33.83% | 0.06 118.57% | -0.19 404.47% | 0.14 171.91% | -0.29 311.21% | -0.07 76.23% | |
revenue per share | 0.01 - | 0.42 4,897.16% | 1.02 142.93% | 0.07 93.64% | 5.32 8,074.36% | 0.01 99.85% | 12.02 145,916.47% | 0.01 99.95% | 4.67 83,183.04% | ||
roe | 0.96 - | 0.89 7.10% | -0.10 111.23% | -0.36 265.22% | -0.42 15.59% | 0.07 116.92% | -0.21 394.55% | 0.16 175.08% | -0.35 320.26% | -0.08 76.47% | |
roic | 0.92 - | -2.79 401.93% | -0.40 85.53% | -0.46 14.55% | -0.45 3.25% | 0.04 109.95% | -0.20 547.22% | 0.13 165.62% | -0.28 318.24% | -0.10 66.24% | |
sales general and administrative to revenue | 54.26 - | 6.01 88.92% | 0.87 85.46% | 15.46 1,668.10% | 0.22 98.58% | 162.45 73,996.90% | 0.11 99.93% | 235.01 208,633.69% | 0.21 99.91% | ||
shareholders equity per share | -0.24 - | -0.99 308.84% | 19.00 2,012.73% | 4.69 75.32% | 8.18 74.38% | 17.27 111.22% | 25.23 46.11% | 31.59 25.20% | 24.12 23.64% | 23.77 1.48% | |
stock based compensation to revenue | 14.91 - | 2.10 85.92% | 0.46 78.08% | 11.20 2,332.66% | 0.15 98.64% | 121.58 79,815.53% | 0.11 99.91% | 224.65 200,234.81% | 0.22 99.90% | ||
tangible asset value | -7.48M - | -29.58M 295.27% | 232.45M 885.88% | 187.49M 19.34% | 391.91M 109.03% | 939.19M 139.65% | 1.66B 77.18% | 2.40B 44.19% | 1.88B 21.84% | 1.88B 0.39% | |
tangible book value per share | -0.26 - | -1.01 295.27% | 18.96 1,978.40% | 4.68 75.32% | 8.17 74.57% | 17.27 111.33% | 25.23 46.13% | 31.59 25.20% | 24.12 23.64% | 23.77 1.47% | |
working capital | -1.18M - | 146.69M 12,552.04% | 298.19M 103.29% | 233.87M 21.57% | 438.65M 87.56% | 930.44M 112.12% | 1.62B 74.36% | 2.30B 41.62% | 1.73B 24.62% | 1.80B 3.89% |
All numbers in (except ratios and percentages)